Liraglutide.
About Liraglutide
Liraglutide is among the compounds studied in metabolic and weight-regulation research. GLP-1 receptor agonist: enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite centrally via hypothalamic and reward-related circuits.
Research Application
Approved for glycemic control in type 2 diabetes (Victoza) and for chronic weight management in obesity (Saxenda). The pivotal SCALE trial demonstrated significant weight loss with 3.0 mg/day versus placebo in 3,731 participants over 56 weeks.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Pi-Sunyer X, et al. N Engl J Med. 2015;373(1):11–22. PMID 26132939
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about Liraglutide?
We reply personally – via email or Telegram.